BridgeBio Pharma secures $299m in funding to accelerate genetic disease drug development
BridgeBio Pharma, a leading clinical-stage biopharma company specialising in treatments for genetic diseases, has raised $299.2 million in a new funding round. The California-based firm plans to use the funds to support its drug development programmes and enhance its research and development (R&D) efforts, specifically focusing on expanding treatments for patients with unmet needs. KKR […]